NC
CHRS icon

Nexthera Capital’s Coherus Oncology CHRS Stock Holding History

Nexthera Capital’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$6.99M Buy
+316,316
New +$5.49M 5.82% 8

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Nexthera Capital's CHRS Position: Q2 2019 in Review

Nexthera Capital opened a new position in Coherus Oncology (CHRS) in Q2 2019: 316,316 shares worth $6.99M. The stake represents 5.82% of the portfolio and ranks #8 among its holdings.

146 funds tracked by Wall St. Rank hold CHRS as of Q2 2019.

  • Nexthera Capital held 316,316 shares of Coherus Oncology worth $6.99M as of Q2 2019.
  • Coherus Oncology was a new Nexthera Capital position in Q2 2019.
  • Coherus Oncology made up 5.82% of Nexthera Capital's portfolio in Q2 2019, its #8 holding.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.